| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cc12f48618be8909d7af78e046b536b7 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D239-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-517
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-94 |
| filingDate |
2010-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c97dce7a0bb0659b905bfb069925f89d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_34097f934799f889a0a55a610783d65b |
| publicationDate |
2011-08-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CN-102146059-A |
| titleOfInvention |
Quinazoline derivatives and preparation method and application thereof |
| abstract |
The invention discloses quinazoline derivatives serving as irreversible tyrosine kinase inhibitors, and use of the derivatives as inhibitors for human epidermal growth factor receptor (EGFR) mutant T790M and anticancer agents. The invention also relates to a preparation method for the quinazoline derivatives, and a medicinal composition containing the quinazoline derivatives. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105073116-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102659764-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105705494-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110372666-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105705494-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/TW-I496783-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-110372666-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9845329-B2 |
| priorityDate |
2010-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |